Other Advanced Technology

Innovation for Nasal Polyp Sufferers

Recurrent Nasal Polyps

Every year more than 500,000 patients in the U.S. undergo endoscopic sinus surgery.1 Of patients with severe nasal polyps who underwent sinus surgery, 60% had their nasal polyps return.

Nasal polyps are inflammatory growths along the lining of nasal and sinus passages that can lead to congestion and obstruction and loss of smell. While medical therapy such as topical or oral steroids can provide temporary relief, oftentimes they are not completely effective and sinus surgery may be required. Unfortunately, recurrence of nasal polyps is one of the leading causes of repeat sinus surgery.3

Advanced Technology

Dr. Vakkalanka at Pacifica ENT now offers SINUVA® (mometasone furoate) Sinus Implant as an alternative to surgery and other treatment options for recurrent nasal polyps. SINUVA is clinically proven to shrink nasal polyps and reduce nasal obstruction/congestion without surgery.4

Non-Surgical Treatment Option

During a routine office visit, your doctor will numb your nose and sinuses with topical and/or local anesthesia. Then the SINUVA Sinus Implant is delivered into the sinus cavity through the nasal opening.

SINUVA’s innovative technology utilizes a 2-in-1 approach: it is designed to open in the sinus cavity and deliver anti-inflammatory medicine to treat nasal polyps.4 The implant softens over time and may be expelled out of the nose on its own or through sneezing or nose blowing. It can be removed at 90 days or earlier at the physician’s discretion.


SINUVA is FDA-approved for the treatment of nasal polyps in patients ≥18 years of age who have had ethmoid sinus surgery. The most common adverse reactions observed in a clinical study were bronchitis, upper respiratory or middle ear infection, headache, lightheadedness, asthma, and nose bleed.

Announcing an Innovative Treatment for Nasal Polyp Sufferers

Have you ever had an ethmoid sinus surgery, but still suffer from recurrent nasal polyps? If yes, you may have discovered that over-the-counter steroidal nasal sprays can only offer minimal relief.

Nasal polyp disease interferes with quality of life, but now Dr. Vakkalanka offers an alternate intervention outside the operating room. Contact Pacifica ENT today to see if you are a candidate for an in-office procedure with the SINUVA Sinus Implants.

Contact Dr. Vakkalanka today to see if SINUVA is right for you.

1. Data on File. MRG 2012 US Markets for ENT and Bronchoscopy.
2. Wynn R, Har-El, G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114:811-813.
3. Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016, 6 Suppl 1:S22-S209. 4. SINUVA Prescribing Information, Intersect ENT. December 2017.


SINUVA® Sinus Implant is a steroid-releasing (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.


If you have a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, do not use SINUVA. Hypersensitivity reactions, including rash, itch, and swelling have been reported with use of steroids. If steroid effects such as Cushing Syndrome and adrenal suppression appear, consult your healthcare professional. SINUVA is made from bioabsorbable polymers designed to soften over time. As the implant softens and polyps decrease, the implant may be expelled out of the nose on its own or with actions such as sneezing or forceful nose blowing. The implant can be removed 90 days after placement or earlier at the physician’s discretion. Repeat administration of SINUVA has not been studied. As with other endoscopic sinus procedures, there are risks associated with the insertion or removal of SINUVA. SINUVA should be inserted by physicians trained in otolaryngology. Discuss risks related to insertion or removal of SINUVA with your healthcare professional. Your healthcare professional will monitor the nasal tissue adjacent to the SINUVA Sinus Implant for any signs of bleeding, irritation, infection, or perforation. SINUVA should not be used in patients with nasal ulcers or trauma. The most common adverse reactions observed (in more than 1% of trial participants) in clinical studies were bronchitis, upper respiratory or middle ear infection, headache, lightheadedness, asthma, and nose bleed. If you experience excessive nasal bleeding, worsening symptoms of infections, viral eye infections, or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, immediately contact a healthcare professional. Close monitoring is recommended if you have a change of vision or a history of increased intraocular pressure, glaucoma and/or cataracts. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch (www.fda.gov/medwatch) or call 1-800-FDA-1088. You may also report side effects to Intersect ENT at 1-866-531-6004. RX Only. For important risk and use information about SINUVA, please go to www.SINUVA.com.